MHLW Relaxes Rules On Loans To Hospitals In Japan
This article was originally published in PharmAsia News
Executive SummaryAs a part of an additional economic stimulus policy, Japan's Ministry of Health, Labor and Welfare increased financial support to hospitals. The Ministry relaxed loan conditions and increased maximum loan amount to a single facility from the current ¥100 million to ¥720 million. Repayment periods for a loan also were extended from 7 years to 10 years. The new policy applies to loans made before the end of March 2010. (Click here for more - Japanese language
You may also be interested in...
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.